Published in Arch Neurol on October 01, 2002
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. J Neurol (2008) 1.51
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol (2005) 1.26
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
A review of structural magnetic resonance neuroimaging. J Neurol Neurosurg Psychiatry (2004) 1.06
Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. PLoS One (2011) 1.05
White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab (2012) 1.04
Whole brain N-acetylaspartate concentration is conserved throughout normal aging. Neurobiol Aging (2012) 0.93
Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol (2005) 0.93
Insula and anterior cingulate GABA levels in posttraumatic stress disorder: preliminary findings using magnetic resonance spectroscopy. Depress Anxiety (2013) 0.92
Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis. Neurology (2012) 0.88
Genetic association of ErbB4 and human cortical GABA levels in vivo. J Neurosci (2011) 0.88
White matter atrophy and cognitive dysfunctions in neuromyelitis optica. PLoS One (2012) 0.87
Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J Neurol (2005) 0.87
Attention and memory dysfunctions in mild multiple sclerosis. Eur Arch Psychiatry Clin Neurosci (2005) 0.84
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol (2013) 0.83
Self-reported gait unsteadiness in mildly impaired neurological patients: an objective assessment through statistical gait analysis. J Neuroeng Rehabil (2012) 0.83
Focal and diffuse cortical degenerative changes in a marmoset model of multiple sclerosis. Mult Scler (2010) 0.80
Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis. Neuroimage Clin (2014) 0.79
Automated whole-brain N-acetylaspartate proton MRS quantification. NMR Biomed (2014) 0.79
Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? Acta Neuropathol Commun (2014) 0.78
The retrovirus/superantigen hypothesis of multiple sclerosis. Cell Mol Neurobiol (2014) 0.77
Variants of ST8SIA1 are associated with risk of developing multiple sclerosis. PLoS One (2008) 0.76
Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies. PLoS One (2016) 0.75
Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis. J Neuroinflammation (2017) 0.75
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Triangulating a cognitive control network using diffusion-weighted magnetic resonance imaging (MRI) and functional MRI. J Neurosci (2007) 5.03
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Evaluating the toxicity of airborne particulate matter and nanoparticles by measuring oxidative stress potential--a workshop report and consensus statement. Inhal Toxicol (2008) 2.53
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol (2014) 2.51
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2013) 2.20
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol (2011) 2.12
Imaging attentional modulation of pain in the periaqueductal gray in humans. J Neurosci (2002) 2.10
Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings. Stroke (2008) 2.07
Two cases of hemichorea-hemiballism with nonketotic hyperglycemia: a new point of view. Neurol Sci (2009) 2.00
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 1.92
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Age-related changes in grey and white matter structure throughout adulthood. Neuroimage (2010) 1.85
Blood oxygenation level dependent contrast resting state networks are relevant to functional activity in the neocortical sensorimotor system. Exp Brain Res (2005) 1.84
EPR line shifts and line shape changes due to spin exchange of nitroxide-free radicals in liquids 4. Test of a method to measure re-encounter rates in liquids employing 15N and 14N nitroxide spin probes. J Phys Chem A (2008) 1.81
Function in the human connectome: task-fMRI and individual differences in behavior. Neuroimage (2013) 1.79
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol (2004) 1.76
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet (2012) 1.71
A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis (2014) 1.62
Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. J Neurol Sci (2009) 1.59
Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol (2006) 1.59
Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery (2003) 1.54
Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain (2004) 1.54
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Med Image Anal (2012) 1.50
Seeing injectable MS therapies differently: they are more similar than different. Neurology (2009) 1.47
Functional anatomy of interhemispheric cortical connections in the human brain. J Anat (2006) 1.45
Mutations in the UBIAD1 gene, encoding a potential prenyltransferase, are causal for Schnyder crystalline corneal dystrophy. PLoS One (2007) 1.42
Subcortical band heterotopia (SBH) in males: clinical, imaging and genetic findings in comparison with females. Brain (2002) 1.37
Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant (2004) 1.34
Videolaparoscopy as rescue therapy and placement of peritoneal dialysis catheters: a thirty-two case single centre experience. Nephrol Dial Transplant (2006) 1.29
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med (2015) 1.28
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 1.27
Combining shape and connectivity analysis: an MRI study of thalamic degeneration in Alzheimer's disease. Neuroimage (2009) 1.26
FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett (2008) 1.24
EPR line shifts and line shape changes due to spin exchange of nitroxide free radicals in liquids: 6. Separating line broadening due to spin exchange and dipolar interactions. J Phys Chem A (2009) 1.22
Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler (2010) 1.22
Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol (2007) 1.22
2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol (2012) 1.21
Persistent organic pollutant residues in human fetal liver and placenta from Greater Montreal, Quebec: a longitudinal study from 1998 through 2006. Environ Health Perspect (2008) 1.20
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Lesion distribution in children with clinically isolated syndromes. Ann Neurol (2008) 1.17
Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep (2012) 1.16
Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol (2008) 1.16
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol (2014) 1.14
N-glycomic changes in serum proteins during human aging. Rejuvenation Res (2007) 1.13
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol (2012) 1.13
Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. Neuroimage (2010) 1.10
Cerebral hemorrhages in CADASIL: report of four cases and a brief review. J Neurol Sci (2013) 1.08
Assessing the effect of a contouring protocol on postprostatectomy radiotherapy clinical target volumes and interphysician variation. Int J Radiat Oncol Biol Phys (2009) 1.07
Automated detection of focal cortical dysplasia lesions using computational models of their MRI characteristics and texture analysis. Neuroimage (2003) 1.07
1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain (2005) 1.07
Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology (2012) 1.07
Screening of ARHSP-TCC patients expands the spectrum of SPG11 mutations and includes a large scale gene deletion. Hum Mutat (2009) 1.07
Differences in saccade dynamics between spinocerebellar ataxia 2 and late-onset cerebellar ataxias. Brain (2011) 1.06
Spastic paraplegia in 'dominant optic atrophy plus' phenotype due to OPA1 mutation. Brain (2011) 1.05
Inner ear abnormalities in four patients with dRTA and SNHL: clinical and genetic heterogeneity. Pediatr Nephrol (2009) 1.05
The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. Ann Neurol (2004) 1.05
Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. PLoS One (2011) 1.05
Communication and proximity effects on outcomes attributable to sense of presence in distance bioinformatics education. BMC Med Educ (2011) 1.05
Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions. Magn Reson Med (2010) 1.03
Trimmed-likelihood estimation for focal lesions and tissue segmentation in multisequence MRI for multiple sclerosis. IEEE Trans Med Imaging (2011) 1.03
Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci (2008) 1.03
Acute unilateral visual loss as the first symptom of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Arch Neurol (2004) 1.03
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Apoptosis in CADASIL: an in vitro study of lymphocytes and fibroblasts from a cohort of Italian patients. J Cell Physiol (2009) 1.02
Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis. Hum Mutat (2005) 1.01
Spastic paraplegia with thin corpus callosum: description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity. Neurogenetics (2006) 1.00
Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. J Magn Reson Imaging (2005) 0.99
Chromosome 10p deletion in a patient with hypoparathyroidism, severe mental retardation, autism and basal ganglia calcifications. Ann Genet (2004) 0.99
Vascular ultrasound for the pre-operative evaluation prior to arteriovenous fistula formation for haemodialysis: review of the evidence. Nephrol Dial Transplant (2008) 0.99
The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study. J Magn Reson Imaging (2005) 0.99
A point mutation in the lariat branch point of intron 6 of NPC1 as the cause of abnormal pre-mRNA splicing in Niemann-Pick type C disease. Hum Mutat (2004) 0.98
Daily torpor is associated with telomere length change over winter in Djungarian hamsters. Biol Lett (2011) 0.98